Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. Test size products are transitioning from 20 µl to 5 µl per test. Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 µl staining volume or per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Read more at www.biolegend.com/testsize regarding the test size change.
Blue Laser (488 nm)
The antibody HLADQ1 reacts with HLA-DQ 4,5,6,7,8,9 but does not react with DQ2, DR or DP. Additional reported (for the relevant formats) applications include: immunohistochemical staining of acetone-fixed frozen sections and formalin-fixed paraffin-embedded tissues.
HLA-DQ is also known as MHC class II DQ monomorphic antigen. The major histocompatibility complex is composed of two heterodimeric glycoproteins (α and β chains) with apparent molecular weights of 27 and 32 kD. In contrast to other MHC class II molecules, both polypeptide chains of HLA-DQ are polymorphic, with the α chain showing an extremely high degree of polymorphism. HLA-DQ is expressed on B cells in the peripheral blood, and weakly expressed on activated T cells and some monocytes. HLA-DQ is absent on hematopoietic progenitors, resting T cells, erythrocytes, and platelets. HLA-DQ is expressed after HLA-DR and HLA-DP in hematopoietic development. HLA-DQ presents peptide fragments mainly from degraded intravesicular and extracellular proteins to CD4+ T lymphocytes. Specific alleles of HLA-DQ have been linked to the pathogenesis of several autoimmune diseases (including diabetes), both as a susceptibility and resistance factor depending on the particular polymorphism.
MHC class II DQ monomorphic antigen, MHC II
Major histocompatability complex composed of two heterodimeric glycoproteins (α and β chain) with apparent molecular weights of 27 and 32 kD. In contrast to other MHC class II molecules, both polypeptide chains of HLA-DQ are polymorphic.
Expressed on B cells in the peripheral blood, weakly on activated T cells and some monocytes. Absent on hematopoietic progenitors, resting T cells, erythrocytes and platelets. Expressed after HLA-DR and HLA-DP in hematopoietic development.
HLA-DQ presents peptide fragments mainly from degraded intravesicular and extracellular proteins to CD4+ lymphocytes. Specific alleles are linked to the pathogenesis of several autoimmune diseases.
1. So AK, et al. 1987. J. Immunol. 139:3506. 2. Gyllensten UB Erlih HA. 1989. Proc. Natl. Acad. Sci. USA 86:9986. 3. Sonderstrup G and McDevitt HO. 2001. J. Clin. Invest. 107:795.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
This data display is provided for general comparisons between formats. Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors. If you need assistance with selecting the best format contact our expert technical support team.
FITC anti-human HLA-DQ
Human peripheral blood lymphocytes stained with HLA-DQ1 FITC
PE anti-human HLA-DQ
Human peripheral blood lymphocytes stained with HLADQ1 PE and overlayed with isotype control